Clinical trials: Artificial Pancreas
Type1 Diabetes
Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID)
The aim of this clinical study is to determine the feasibility, safety, and preliminary effectiveness of the Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system in pediatric subjects with type 1 diabetes in an…
- Trial name
- HY-GRAID (NCT04255381)
- Testing
- Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Type1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
- Trial name
- iDCL (NCT02985866)
- Testing
- Artificial Pancreas, Sensor Augmented Therapy
- Where
- 7 sites in United States
- Volunteers
- 127 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02846857
- Testing
- 15-week intervention with sensor-augmented pump, 15-week intervention with single-hormone closed-loop, 15-week intervention with dual-hormone closed-loop
- Sponsor
- Institut de Recherches Cliniques de Montreal
Liver Disease
Effect of Preoperative Supplementation in Insulin Resistance
To elucidate the effect of preoperative supplementation of carbohydrate and branched-chain amino acids on postoperative insulin resistance in patients undergoing hepatic resection, we set a randomized trial.
- Trial name
- NCT00657124
- Testing
- Aminolevan EN
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Kochi University
Type 1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
The objective of the study is to assess efficacy and safety of a closed loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial.
- Trial name
- DCLP3 (NCT03563313)
- Testing
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP)
- Where
- 7 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Type 1
Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop
There are many recent advances in insulin treatment of type 1 Diabetes Mellitus (T1DM), however after a meal sugars are always a concern.
- Trial name
- NCT02328040
- Testing
- Sitagliptin and insulin/novolog via CL
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Albert Einstein College of Medicine
Neoplasms (Cancer / Tumors), Colorectal Neoplasms
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment
Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typically using immunohistochemistry or sequencing.
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms
- Trial name
- FATHOM (NCT07814872)
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients.
- Conditions
- Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Machine Learning, Deep Learning
- Trial name
- NCT06278272
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Changhai Hospital
Type 1 Diabetes
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs.
- Trial name
- NCT01833988
- Testing
- Bi-hormonal Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus, Cognitive Change
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
The objective of this pilot study is (i) to test the use of an Artificial Pancreas (AP) System as a viable therapy treatment for two vulnerable populations: 6 to 10 year-old and adults older ≥65 years old with T1D; (ii) to assess…
- Trial name
- NCT03674281
- Testing
- SAP, CLC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Pancreatic Disease, Cardiovascular Diseases
Tight Glycemic Control by Artificial Pancreas
Hyperglycaemia has been repeatedly associated with risk of mortality and morbidity in the intensive care unit (ICU). The evidence currently available is in favour of a 'normal ≤ 6.1 mmol/l' level for blood glucose control in ICUs…
- Trial name
- KMS (NCT00735228)
- Testing
- Artificial pancreas
- Where
- Japan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kochi University
Type 1 Diabetes, Diabetic Kidney Disease
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range.
- Conditions
- Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction
- Trial name
- MANATEE-T1D (NCT05065372)
- Testing
- Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Kalie Tommerdahl
Pancreatic Neoplasm
Tight Glycemic Control by Artificial Pancreas
This study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection.
- Trial name
- NCT00657995
- Testing
- Artificial Pancreas (STG-22)
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Kochi University
Type 1 Diabetes
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition
- Trial name
- NCT04084171
- Testing
- Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Type 1
An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes
Closed-loop systems are becoming an integral part of diabetes management. These systems were uniformly proven to improve glycemic control, reduce hyperglycemia and hypoglycemia while modestly reducing HbA1c levels and improving…
- Trial name
- NCT04269668
- Testing
- Medtronic Minimed 670G 3.0 HCL, Medtronic Minimed 670G 4.0 AHCL
- Where
- 2 sites in Germany, Israel
- Volunteers
- 28 people
- Sponsor
- Rabin Medical Center
Type 1 Diabetes
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms
Objective: to gain experience with in-home use of a modified algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is projected overnight and to obtain…
- Trial name
- PHM2 (NCT02438189)
- Testing
- Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
- Where
- 3 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes Mellitus in Prepubertal Children
Efficacy of Closed-loop Insulin Therapy in Prepubertal Child in Free-life
The study is a randomized trial preceded by a run-in period and followed by a non-randomized study extension. After 3 weeks of outpatient use of study pump (1 week) and study pump+CGM (2weeks) as run-in period, patient and…
- Trial name
- FREELIFE-KID (NCT03739099)
- Testing
- Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
- Where
- France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Montpellier
Diabetes
Efficacy of Automated Insulin Therapy Early Initiated After Diagnosis on Blood Glucose Control in Children and Adolescents With Type 1 Diabetes
The main objective is to assess whether hybrid closed-loop (HCL) insulin delivery initiated early after diagnosis of Type 1 diabetes (T1D) allows a better efficacy on glucose control than conventional standard insulin therapy…
- Trial name
- APATDIAGNOSIS (NCT06283797)
- Testing
- OmniPod 5, Dexcom G6, PAID questionnaires
- Where
- 4 sites in France
- Volunteers
- 112 people
- Sponsor
- University Hospital, Montpellier
Diabetes Mellitus, Type 1 Diabetes
The Insulin-Only Bionic Pancreas Pivotal Trial
This multi-center randomized control trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas (BP) System versus Usual Care (UC) during a 13-week study period.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
- Trial name
- NCT04200313
- Testing
- Bionic Pancreas (BP) with Aspart or Lispro, Bionic Pancreas with Fiasp (BPFiasp), Usual Care (UC)
- Where
- 16 sites in United States
- Volunteers
- 440 people
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes
Insulet Artificial Pancreas Early Feasibility Study
The purpose is to perform an early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the OmniPod® Insulin Management System and gather clinical data that will be used to make…
- Trial name
- NCT02897557
- Testing
- Insulet Artificial Pancreas (AP) System
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Insulet Corporation